Friday, 17 Aug 2018

You are here

Teriparatide Superior to Risedronate in the VERO Trial

Lancet reports that in a study teriparatide with risedronate, post-menopausal women with severe osteoporosis had significantly fewer new vertebral and clinical fractures on teriparatide comared to those receiving risedronate.

This trial is one of the first to compare osteoporosis drugs with incident fractures as the primary outcome.

Post-menopausal women (n=680) with more than one severe vertebral fracture and a BMD T score of less than or equal to −1·50 were enrolled to receive 20 μg of teriparatide (TER) daily or 35 mg of oral risedronate (RIS) once weekly for 24 months. The primary outcome was new radiographic vertebral fractures.

After 24 months, fewer new vertebral fractures (5·4%) were seen in the TER patients vs. RIS group (12·0%) (p<0·0001).

Clinical fractures were also decreased in the TER patients (4·8% vs. 9·8%). Non-vertebral fragility fractures were not significant but were also lowere (4% vs 6·1%). 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Persistent Osteoporosis Drug Use Pays Off

Among elderly female Medicare patients, persistent use of osteoporosis medications was associated with reduced risk of fracture and significantly lower total health care costs.

Osteoporosis International reports the results of research examining records of 294,369 women >65 years old, on Medicare and taking osteoporosis medicines for the first time at some point between 2009 and 2011. (Citation Source: bit.ly/2vALm98) 

Fractures Augment 10 Year Mortality Risks

This nationwide study of adults (50+ yrs) from Denmark has shown that following a fragility fracture, the 10-years mortality risk was increased, especially in the first year following the fracture. 

Early Hip Fracture Surgery Reduces Mortality

CMAJ reports that seniors are more likely to survive a hip fracture if the surgery is done as soon as they’re admitted to the hospital - suggesting hospitals should expedite operating room access for patients whose surgery has already been delayed for nonmedical reasons. (Citation source: bit.ly/2KzdrCt) 

Big Advances for Two Osteoporosis Drugs

New developments with the FDA and new scientific findings are adding momentum to two drugs experts believe are game-changers in osteoporosis treatment.

In May, the FDA approved denosumab (Prolia) for use in patients who have glucocorticoid-induced osteoporosis and are at high risk of fracture. 

Update on Osteoporosis

This session was an update on the management of osteoporosis given by Professor Christian Roux from France.

He emphasised the use of composite risk score like the FRAX. He highlighted that the risk of vertebral fracture is increased by both the recency and severity of previous vertebral fracture. So it is important that those with vertebral fractures are followed up and treated appropriately to prevent subsequent fractures.